Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
422 participants
INTERVENTIONAL
2004-11-30
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
BAY86-5016, SH P00331F
Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
Arm 2
SH P00331N
Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BAY86-5016, SH P00331F
Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
SH P00331N
Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wörgl, Tyrol, Austria
Bregenz, , Austria
Graz, , Austria
Vienna, , Austria
Vienna, , Austria
Zeltweg, , Austria
Helsinki, , Finland
Helsinki, , Finland
Turku, , Finland
Turku, , Finland
Paris, Paris, France
Biarritz, , France
Bordeaux, , France
Compiègne, , France
Compiègne, , France
Maisons Lafitte, , France
Montargis, , France
Nancy, , France
Pantin, , France
Roanne, , France
Saint-Germain-en-Laye, , France
Toulouse, , France
San Fernando, Cádiz, Spain
Pontevedra, Galicia, Spain
Salt, Girona, Spain
Guadalajara, Guadalajara, Spain
Barcelona, , Spain
Santiago de Compostela, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find information about studies related to Bayer Healthcare products conducted in Europe.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2004-000821-31
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
307969
Identifier Type: OTHER
Identifier Source: secondary_id
91402
Identifier Type: -
Identifier Source: org_study_id